At 11.4% CAGR, the Asia Pacific Gastric Cancer Diagnostic Procedure Market is projected to be worth US$ 349.33 million by 2028, says The Business Market Insights

According to the Business Market Insights’ research, the Asia Pacific gastric cancer diagnostic procedure market was valued at US$ 182.85 million in 2022 and is expected to reach US$ 349.33   million by 2028, registering a CAGR of 11.4 % from 2022 to 2028.  Rise in prevalence of gastrointestinal diseases and surging cases of helicobacter pylori infection are the critical factors attributed to the Asia Pacific gastric cancer diagnostic procedure market expansion.                    

No Stomach For Cancer (NSFC), a nonprofit organization, contributes to spreading awareness and educating people about stomach cancer. The organization supports research focused on screening, early detection, treatment, and prevention of stomach cancer. Hope For Stomach Cancer is another nonprofit organization that offers resources to patients, caregivers, and loved ones while promoting early detection and prevention in general and medical communities. The organization develops and facilitates programs that assist stomach cancer patients to live the best possible life throughout the phases of the disease. Therefore, a rising number of gastric cancer awareness programs are expected to offer lucrative opportunities for the gastric cancer diagnostic procedures market during the forecast period are fueling the growth of the Asia Pacific gastric cancer diagnostic procedure market

On the contrary, shortage of medical laboratory professionals hurdles the growth of Asia Pacific gastric cancer diagnostic procedure market.

Based on healthcare providers, the Asia Pacific gastric cancer diagnostic procedure market is segmented into diagnostic laboratories, hospitals, cancer research institutes, oncology specialty clinics, and others. The hospitals segment held 43.5% market share in 2022, amassing US$ 79.52 million. It is projected to garner US$ 148.91 million by 2028 to expand at 11.00 % CAGR during 2022–2028.

Based on symptoms type, the Asia Pacific gastric cancer diagnostic procedure market is segmented into Symptomatic and Asymptomatic. The Asymptomatic segment held 80.0% market share in 2022, amassing US$ 146.24 million. It is projected to garner US$ 276.89 million by 2028 to expand at 11.2 % CAGR during 2022–2028.

Based on body fluid, the Asia Pacific gastric cancer diagnostic procedure market is segmented into body fluid Blood, urine, saliva, stomach wash/gastric juice, tissue and others. Blood segment held 53.3% market share in 2022, amassing US$ 97.44 million. It is projected to garner US$ 190.34 million by 2028 to expand at 11.8 % CAGR during 2022–2028

Based on Diagnostic procedure, the Asia Pacific gastric cancer diagnostic procedure market is categorized into Endoscopic procedure, Biopsy and tissue tests, lab test, In-vitro diagnostic tests, Imaging Test, Molecular Diagnostics, Multiplexing molecular Diagnostics, Immunoassay, and others. The imaging segment held 42.2% market share in 2022. It was assessed at US$ 77.08 million in 2022 and is likely to hit US$ 145.38 million by 2028, exhibiting a CAGR of 11.2% during the forecast period

Based on offering, the Asia Pacific gastric cancer diagnostic procedure market is segmented into instruments, reagents & consumables, and services. Reagents & Consumables segment held 49.0% market share in 2022, amassing US$ 89.60 million. It is projected to garner US$ 167.22 million by 2028 to expand at 11.0 % CAGR during 2022–2028.  

Based on disease condition, the Asia Pacific gastric cancer diagnostic procedure market is segmented into early gastric cancer and gastric cancer advanced types. The Gastric cancer advanced type segment held 79.8% market share in 2022, amassing US$ 146.00 million. It is projected to garner US$ 280.80 million by 2028 to expand at 11.5% CAGR during 2022–2028.

Based on country, the Asia Pacific gastric cancer diagnostic procedure market has been categorized into  China, India, Japan, South Korea, Australia, and the rest of Asia Pacific.  Our regional analysis states that China captured 29.25% market share in 2022. It was assessed at US$ 53.48 million in 2022 and is likely to hit US$ 101.13 million by 2028, exhibiting a CAGR of 11.0% during the forecast period.

Key players dominating the Asia Pacific gastric cancer diagnostic procedure market are Atlas-Link Biotech Co Ltd; Bio-Rad Laboratories Inc; MiRXES Pte Ltd; Agilent Technologies Inc; F. Hoffmann-La Roche Ltd; bioMerieux SA; Thermo Fisher Scientific Inc; Illumina Inc; Vela Diagnostics Holding Pte Ltd; and Myraid Genetics Inc among others.   

• In Aug 2022, MiRXES launched a series of new capabilities—including an Industry 4.0 manufacturing facility, two new laboratories, and a collaborative multi-cancer screening research project. The new developments are aligned with MiRXES’ goal of advancing its research and production capabilities to develop miRNA-based disease detection tests.  
• In Jan 2023, Agilent Technologies announced a partnership with Akoya Biosciences to develop chromogenic and immunofluorescent multiplex assays that include spatial analysis for biopharma companies developing precision cancer therapeutics. This partnership enables an ecosystem that assists the development of novel precision cancer therapeutics and offers a streamlined workflow to our joint customers in the clinical research market to meet the needs of future clinical diagnostics.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com